The Effect of Statins in Cancer Risk Reduction in Patients on Dialysis: A Population-Based Case-Control Study

Overview

Journal J Clin Med

Specialty General Medicine

Date 2021 Dec 10

PMID 34884304

Citations 2

Authors

Po-Huang Chen

Hong-Jie Jhou

Chi-Hsiang Chung

Cho-Hao Lee

Yi-Ying Wu

Wei-Chou Chang

Wu-Chien Chien

Ping-Ying Chang

Affiliations

Soon will be listed here.

Abstract

Background: To realize whether statins reduce the risk of cancer in susceptible dialysis populations, this study analyzed the relationship between statin use and cancer risk in patients on dialysis.

Methods: Patients having a history of chronic kidney disease with hemodialysis or peritoneal dialysis and receiving statin prescriptions or not were enrolled. The main outcome was cancer diagnosis. This study used univariate and multivariate Cox regression analyses.

Results: In total, 4236 individuals in the statin group and 8472 individuals in the statin nonuser group were included in the study. Multivariate Cox regression analysis revealed that statin users are significantly less likely to develop cancer than statin nonusers (adjusted hazard ratio (HR) 0.81, 95% confidence interval (CI) 0.78-0.90). Subgroup analyses revealed that statin cumulative defined daily doses >365 were associated with a significantly decreased risk of cancer incidence (adjusted HR 0.59, 95% CI 0.45-0.87), and statin users have a reduced risk of respiratory, soft tissue and connective tissue, breast, gynecological, prostate, central nervous system, and lymphatic and hematopoietic cancer than nonusers.

Conclusions: Our population-based cohort study provides an association that statins reduce the risk of malignancy in patients on dialysis, especially with a longer treatment duration, and certain types of cancer.

Citing Articles

Mutant p53, the Mevalonate Pathway and the Tumor Microenvironment Regulate Tumor Response to Statin Therapy.

Pereira M, Matuszewska K, Glogova A, Petrik J Cancers (Basel). 2022; 14(14).

PMID: 35884561 PMC: 9323637. DOI: 10.3390/cancers14143500.

Incidence and Risk Factors for Venous Thromboembolism in Female Patients Undergoing Breast Surgery.

Londero A, Bertozzi S, Cedolini C, Neri S, Bulfoni M, Orsaria M Cancers (Basel). 2022; 14(4).

PMID: 35205736 PMC: 8870485. DOI: 10.3390/cancers14040988.

References

Zhang Y, Liang M, Sun C, Qu G, Shi T, Min M . Statin Use and Risk of Pancreatic Cancer: An Updated Meta-analysis of 26 Studies. Pancreas. 2019; 48(2):142-150. DOI: 10.1097/MPA.0000000000001226. View

. KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update. Am J Kidney Dis. 2012; 60(5):850-86. DOI: 10.1053/j.ajkd.2012.07.005. View

Bjarnadottir O, Romero Q, Bendahl P, Jirstrom K, Ryden L, Loman N . Targeting HMG-CoA reductase with statins in a window-of-opportunity breast cancer trial. Breast Cancer Res Treat. 2013; 138(2):499-508. DOI: 10.1007/s10549-013-2473-6. View

Tan P, Zhang C, Wei S, Tang Z, Gao L, Yang L . Effect of statins type on incident prostate cancer risk: a meta-analysis and systematic review. Asian J Androl. 2016; 19(6):666-671. PMC: 5676426. DOI: 10.4103/1008-682X.190327. View

Lian X, Wang G, Zhou H, Zheng Z, Fu Y, Cai L . Anticancer Properties of Fenofibrate: A Repurposing Use. J Cancer. 2018; 9(9):1527-1537. PMC: 5950581. DOI: 10.7150/jca.24488. View

Jung J, Bae G, Kang M, Kim S, Lee D . Statins and All-Cause Mortality in Patients Undergoing Hemodialysis. J Am Heart Assoc. 2020; 9(5):e014840. PMC: 7335561. DOI: 10.1161/JAHA.119.014840. View

Wankowicz P, Staszewski J, Debiec A, Nowakowska-Kotas M, Szylinska A, Turon-Skrzypinska A . Pre-Stroke Statin Therapy Improves In-Hospital Prognosis Following Acute Ischemic Stroke Associated with Well-Controlled Nonvalvular Atrial Fibrillation. J Clin Med. 2021; 10(14). PMC: 8305559. DOI: 10.3390/jcm10143036. View

Bonovas S, Nikolopoulos G, Bagos P . Use of fibrates and cancer risk: a systematic review and meta-analysis of 17 long-term randomized placebo-controlled trials. PLoS One. 2012; 7(9):e45259. PMC: 3446944. DOI: 10.1371/journal.pone.0045259. View

Baigent C, Landray M, Reith C, Emberson J, Wheeler D, Tomson C . The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011; 377(9784):2181-92. PMC: 3145073. DOI: 10.1016/S0140-6736(11)60739-3. View

10.

Yu I, Fang J, Tsai Y . Exploring demands of hemodialysis patients in Taiwan: A two-step cluster analysis. PLoS One. 2020; 15(2):e0228259. PMC: 7006915. DOI: 10.1371/journal.pone.0228259. View

11.

Wu Q, Tu C, Li Y, Zhu J, Qian K, Li W . Statin use and breast cancer survival and risk: a systematic review and meta-analysis. Oncotarget. 2015; 6(40):42988-3004. PMC: 4767486. DOI: 10.18632/oncotarget.5557. View

12.

Cho S, Yang Y, Liu Y, Hsiao H, Huang C, Wu C . Previous Exposure to Statin May Reduce the Risk of Subsequent Non-Hodgkin Lymphoma: A Nationwide Population-Based Case-Control Study. PLoS One. 2015; 10(10):e0139289. PMC: 4591168. DOI: 10.1371/journal.pone.0139289. View

13.

Chen B, Chiu H, Yang C . Statins are Associated With a Reduced Risk of Brain Cancer: A Population-Based Case-Control Study. Medicine (Baltimore). 2016; 95(17):e3392. PMC: 4998687. DOI: 10.1097/MD.0000000000003392. View

14.

El-Serag H, Johnson M, Hachem C, Morgana R . Statins are associated with a reduced risk of hepatocellular carcinoma in a large cohort of patients with diabetes. Gastroenterology. 2009; 136(5):1601-8. PMC: 2677134. DOI: 10.1053/j.gastro.2009.01.053. View

15.

Giacomini I, Gianfanti F, Desbats M, Orso G, Berretta M, Prayer-Galetti T . Cholesterol Metabolic Reprogramming in Cancer and Its Pharmacological Modulation as Therapeutic Strategy. Front Oncol. 2021; 11:682911. PMC: 8181394. DOI: 10.3389/fonc.2021.682911. View

16.

Yanik E, Clarke C, Snyder J, Pfeiffer R, Engels E . Variation in Cancer Incidence among Patients with ESRD during Kidney Function and Nonfunction Intervals. J Am Soc Nephrol. 2015; 27(5):1495-504. PMC: 4849829. DOI: 10.1681/ASN.2015040373. View

17.

Docrat T, Nagiah S, Krishnan A, Naidoo D, Chuturgoon A . Atorvastatin induces MicroRNA-145 expression in HEPG2 cells via regulation of the PI3K/AKT signalling pathway. Chem Biol Interact. 2018; 287:32-40. DOI: 10.1016/j.cbi.2018.04.005. View

18.

Jeong G, Lee K, Kim J, Eisenhut M, Kronbichler A, van der Vliet H . Effect of Statin on Cancer Incidence: An Umbrella Systematic Review and Meta-Analysis. J Clin Med. 2019; 8(6). PMC: 6617015. DOI: 10.3390/jcm8060819. View

19.

Freeman M, Solomon K, Moyad M . Statins and the risk of cancer. JAMA. 2006; 295(23):2720-1. DOI: 10.1001/jama.295.23.2720-b. View

20.

Cauley J, McTiernan A, Rodabough R, Lacroix A, Bauer D, Margolis K . Statin use and breast cancer: prospective results from the Women's Health Initiative. J Natl Cancer Inst. 2006; 98(10):700-7. DOI: 10.1093/jnci/djj188. View